Conclusion
The annual prevalence of OCS use among young adults with asthma in
Denmark is almost 5%. Though the proportion of OCS users has increased
slightly in the years 1999-2018, we observed an interesting shift
towards use of lower overall OCS doses. We found that OCS use at ≥5 mg
per day was rare and decreasing. These findings may aid as an
evidence-based foundation in the ongoing discussion of asthma management
and OCS sparing initiatives.
Data availability : The regulations of data sharing defined by
standard terms for research projects and Danish Act on Processing of
Personal Data will be followed.
https://www.datatilsynet.dk/english/
Conflict of interest :
IRS reports grants paid to her institution from AstraZeneca, Teva, the
Odd Fellow Lodge of Haderslev Denmark, the Region of Southern Denmark,
and the University of Southern Denmark during the conduct of the study;
and personal fees for lectures from Roche and grants from Novartis,
outside the submitted work.
HM has nothing to disclose.
DPH has nothing to disclose.
AP reports grants from Alcon, grants from Almirall, grants from
Astellas, grants from Astra-Zeneca, grants from Boehringer-Ingelheim,
grants from Novo Nordisk, grants from Servier, grants from LEO Pharma,
outside the submitted work.
JRD reports grants and personal fees for advisory board participation
and lectures from Roche and Boehringer Ingelheim, and personal fees for
lectures from Chiesi, outside the submitted work.
Author contribution : All authors participated in the study
design. IRS wrote the first draft of the paper. All authors interpreted
the data and revised the paper with approval of the final version. JRD
was the head supervisor of the project.
Ethical approval : Register-based studies do not require
approval from ethical boards in Denmark due to the use of pseudomized
data. The study was approved by the Danish Data Protection Agency.